A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
Published online on February 28, 2026
Abstract
Journal of Psychopharmacology, Ahead of Print.
Aims:To evaluate the safety and effect on clinical outcomes of depression of Beckley Psytech Ltd (BPL)-003, an intranasal formulation of 5-methoxy-N,N-dimethyltryptamine, in patients with moderate-to-severe major depressive disorder (MDD) with treatment-...
Aims:To evaluate the safety and effect on clinical outcomes of depression of Beckley Psytech Ltd (BPL)-003, an intranasal formulation of 5-methoxy-N,N-dimethyltryptamine, in patients with moderate-to-severe major depressive disorder (MDD) with treatment-...